| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NGNE | Common Stock | 1,668,357 | 25 Nov 2024 | By Samsara BioCapital, L.P. | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NGNE | Pre-Funded Warrants (Right to Buy) | 25 Nov 2024 | Common Stock | 67,070 | By Samsara BioCapital, L.P. | F1, F2, F3 | |||||||
| holding | NGNE | Pre-Funded Warrants (Right to Buy) | 25 Nov 2024 | Common Stock | 20,000 | $0.001000 | By Samsara BioCapital, L.P. | F1, F2 |
| Id | Content |
|---|---|
| F1 | Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| F2 | The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. |
| F3 | The exercise price of the Pre-Funded Warrants is $0.000001. |